Division of Marketing & Communication - The Hebrew University of Jerusalem
 
Search:  
Advanced Search   Gallery  
About Us  
Contact Us   ňářéú
Latest Releases:   Press Releases:
Supreme Court Deputy-President Eliezer Rivlin (ret.) Joins Hebrew University Faculty of LawSupreme Court Deputy-President Eliezer Rivlin (ret.) Joins Hebrew University Faculty of Law
Not just our cars, but also living organisms need antifreeze to survive in the cold  Not just our cars, but also living organisms need antifreeze to survive in the cold
Nobel laureate Dr. Bruce Beutler to lecture, receive award at Lautenberg Center for Immunology and Cancer ResearchNobel laureate Dr. Bruce Beutler to lecture, receive award at Lautenberg Center for Immunology and Cancer Research
Learn in Israel, Heal the World: Public health leaders from 20 countries will spend nine days learning and exchanging ideas in JerusalemLearn in Israel, Heal the World: Public health leaders from 20 countries will spend nine days learning and exchanging ideas in Jerusalem
Music on our Minds: international conference on music and the brain will mix science and concertsMusic on our Minds: international conference on music and the brain will mix science and concerts
German foundation awards two €250,000 prizes to Hebrew University researchers in Humanities and Social SciencesGerman foundation awards two €250,000 prizes to Hebrew University researchers in Humanities and Social Sciences
Professor Yoram Bilu to receive Israel Prize in sociological and anthropological researchProfessor Yoram Bilu to receive Israel Prize in sociological and anthropological research
How to cut down on crime? Focus police in concentrated ‘hot spots,’ says Hebrew University criminologist How to cut down on crime? Focus police in concentrated ‘hot spots,’ says Hebrew University criminologist
Healing the world: 70 graduates of International Master’s in Public Health program to attend 2nd alumni workshop, reunion in JerusalemHealing the world: 70 graduates of International Master’s in Public Health program to attend 2nd alumni workshop, reunion in Jerusalem
It's a bird, it's a plane, it's…. Hebrew U?It's a bird, it's a plane, it's…. Hebrew U?
 
04 June, 2008

Synthetic molecules developed by Hebrew University researchers hold promise for new family of anti-cancer drugs

Prof. Shimon Gatt (left) and Dr. Arie Dagan in their laboratory at the Hebrew University-Hadassah Medical School (Photo: Sasson Tiram)
Prof. Shimon Gatt (left) and Dr. Arie Dagan in their laboratory at the Hebrew University-Hadassah Medical School (Photo: Sasson Tiram)

Synthetic molecules designed by two Hebrew University of Jerusalem researchers have succeeded in reducing and even eliminating the growth of human malignant tissues in mice, while having no toxic effects on normal tissue.

For their work in developing these harbingers of a possible new generation of anti-cancer drugs, Dr. Arie Dagan and Prof. Shimon Gatt of the Department of Biochemistry of the Hebrew University-Hadassah Medical School will be among those receiving the Kaye Award for Innovation on June 4 during the 71st meeting of the Hebrew University of Jerusalem Board of Governors.

The molecules developed by Dagan and Gatt affected the metabolism of various sphingolipids and consequently those of cancer cells. Sphingolipids are a family of complex lipid molecules that are involved in signaling pathways that mediate cell growth, differentiation and death.

Several of the most active molecules developed by Dagan and Gatt are derivatives of ceramide (a member of the sphingolipid family). Ceramide induces programmed cell death (apoptosis) in a variety of cancer cells.

The natural levels of ceramide in cancer cells are generally too low to induce a therapeutic effect. In preclinical studies to date, various treatments with the synthetic molecules resulted in an elevation of ceramide levels in cancer cells, thereby leading to their death by apoptosis. In addition, these synthetic molecules appear to be synergistic with chemotherapeutic drugs.

Dagan and Gatt state that their studies demonstrated that their synthetic compounds reduced considerably the sizes of pancreatic, prostate and breast tumors with little or no effects on normal cells and tissues. The researchers see this as a precursor to the development of a new generation of anti-cancer drugs that induce, selectively, apoptosis only to tumorous cells. These drugs are expected to be highly effective while inducing fewer side effects than current anti-cancer drugs.

Prof. Shimon Gatt and Dr. Arie Dagan’s development of synthetic sphingolipid analogs as anti-cancer drugs is patented by Yissum, the technology transfer company of the Hebrew University of Jerusalem. Yissum licensed the technology to BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange,, for the development of these synthetic molecules as anti-cancer drugs.

The Kaye Innovation Awards have been given annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society.



Downloadable File: KayeGattDagan.doc

 

© All rights reserved to The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Division of Marketing & Communication